AVBP Company Profile and Key Details

NASDAQ : AVBP

ArriVent BioPharma

$27.97

-0.6-2.10%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ArriVent BioPharma, Inc. (AVBP) stock declined over -2.10%, trading at $27.97 on NASDAQ, down from the previous close of $28.57. The stock opened at $28.50, fluctuating between $27.67 and $28.52 in the recent session.

Stock Snapshot

28.57

Prev. Close

1.3B

Market Cap

27.665

Day Low

-8.06

P/E Ratio

-3.47

EPS (TTM)

N/A

Cash Flow per Share

28.5

Open

46.57M

Number of Shares

28.52

Day High

53.25%

Free Float in %

N/A

Book Value

299.05K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 15, 2026	28.51	28.75	27.70	27.97	299.05K
Sep 14, 2026	29.10	29.83	28.40	28.57	538.34K
Sep 11, 2026	29.16	29.21	28.15	29.00	1.13M
Sep 10, 2026	29.33	30.53	28.54	28.70	564.17K
Sep 09, 2026	30.02	30.26	29.40	29.79	280.14K
Sep 08, 2026	30.57	31.40	30.02	30.28	721.64K
Sep 04, 2026	30.79	31.45	30.60	30.95	182.37K
Sep 03, 2026	30.58	31.39	30.22	31.03	465.36K
Sep 02, 2026	30.33	30.79	29.60	30.51	423.86K
Sep 01, 2026	30.10	30.33	29.70	30.15	356.09K
Aug 31, 2026	29.94	30.26	29.35	30.05	369.57K
Aug 28, 2026	30.53	31.37	29.75	30.17	353.46K
Aug 27, 2026	30.79	31.77	30.24	31.00	299.97K
Aug 26, 2026	31.21	31.41	30.11	31.14	433.84K
Aug 25, 2026	28.64	31.52	28.64	31.35	961.65K
Aug 24, 2026	29.02	29.02	28.05	28.26	225.57K
Aug 21, 2026	29.45	29.77	28.95	29.12	304.81K
Aug 20, 2026	29.73	29.81	28.64	29.18	406.27K
Aug 19, 2026	30.13	30.45	29.31	30.02	522.83K
Aug 18, 2026	28.86	30.37	28.86	30.00	408.73K

Contact Details

Newtown Square, PA 19073

United States

https://arrivent.com 628 277 4836

About Company

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Stock Peers

ARGX

-10.78-1.09%

argenx SE$979.76 REGN

-19.63-2.47%

Regeneron Pharmaceuticals, Inc.$774.11 MDGL

-16.8-3.11%

Madrigal Pharmaceuticals, Inc.$523.26 VRTX

-4.88-0.94%

Vertex Pharmaceuticals Incorporated$514.63 UTHR

-2.35-0.47%

United Therapeutics Corporation$500.35 ONC

-7.33-2.07%

BeOne Medicines AG$346.50 KRYS

-3.35-0.99%

Krystal Biotech, Inc.$336.68 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-17.65-5.34%

Praxis Precision Medicines, Inc.$312.90 LGND

-3.67-1.31%

Ligand Pharmaceuticals Incorporated$276.98

Company Overview

ArriVent BioPharma, Inc. (NASDAQ:AVBP) closed at $27.97 USD, losing -$0.60 (-2.10%) from the previous close of $28.57. The stock is currently mid-range between its 52-week high and low $17.00 and $35.83. With a market capitalization of about $1.30 billion, ArriVent BioPharma, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 535.57 thousand shares, volume is running light vs its 52-week average. Headquartered in Newtown Square, PA, ArriVent BioPharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zhengbin Yao, the company employs approximately 77 people and listed since January 26, 2024. ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Technical Performance

AVBP has shown sold momentum, gaining 8.9% over the past week and 14.1% over the past quarter, though year-to-date performance is up 10.64%. Short-term trend indicators are bearishly aligned (SMA20 3.26%, SMA50 5.34%, SMA200 11.15%). The stock’s 14-day RSI is 56.48 (neutral), while the ATR of 1.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.76% below its high and over 50.16% above its low. Average 10-day trading volume of 589.22 thousand shares is slightly above the 3-month average of 527.79 thousand, indicating heightened recent market interest.

Valuation Metrics

ArriVent BioPharma, Inc. trades at a P/E ratio of -7.62, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.64 trading at moderately above to book value. The P/FCF stands at -8.83, also below market averages.

Dividend & Fair Value

ArriVent BioPharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.18. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of -5.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $31.00. The high target offers 78.76% upside. The low target suggests 10.83% downside. The mean target is $42.36. This offers 51.45% upside. ArriVent BioPharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 12, 2026, missed forecasts by 6.35%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include 187.88% in May 12, 2025.

Shareholding & Insider Activity

ArriVent BioPharma, Inc. has 49.31 million shares outstanding. The public float is 32.11 million shares, elevated short interest at 18.70% of float. This equals 8.69 million shares. The short ratio is 21.25 days. Institutional investors hold 97.72% of the float. Insiders own 1.63%. HILLHOUSE INVESTMENT MANAGEMENT, LTD. holds 3.93 million shares, HEALY JAMES has 1.70 million shares and GORDON CARL L has 1.51 million shares.

Financial & Profitability Overview

Over the trailing twelve months, ArriVent BioPharma has not generated any revenue.
On valuation metrics, ArriVent BioPharma trades at a P/E of -7.62, P/S of 0.00 and P/B of 3.64. The current ratio is 14.16 and quick ratio is 14.16. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -421.45.

Price Forecast & Outlook

Our AI price prediction model suggests that ArriVent BioPharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.75%, with price expected at $28.46 by September 29, 2026, within a range of $27.53 to $29.45 3-Month Outlook: Projected rise of 125.13%, reaching $62.97 by December 11, 2026, with a range of $61.71 to $64.84. 1-Year Outlook: Projected gain of 8.47%, with price at $30.34 by September 15, 2027, within a range of $28.89 to $32.00.

Key Takeaways

ArriVent BioPharma, Inc. (NASDAQ:AVBP) shares are up 10.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ArriVent BioPharma, Inc. trading at a premium to the broader market with a P/E of -7.62. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $39.70, suggesting 41.94% upside. Our AI forecast model points to short-term strength (1.75% over two weeks), a medium-term rise (125.13% over three months), and a longer-term gain (8.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ArriVent BioPharma, Inc. (AVBP) stock price?

ArriVent BioPharma, Inc. (NASDAQ: AVBP) stock price is $27.97 in the last trading session. During the trading session, AVBP stock reached the peak price of $28.52 while $27.67 was the lowest point it dropped to. The percentage change in AVBP stock occurred in the recent session was -2.1% while the dollar amount for the price change in AVBP stock was - $0.60.

AVBP's industry and sector of operation?

The NASDAQ listed AVBP is part of Biotechnology industry that operates in the broader Healthcare sector. ArriVent BioPharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AVBP?

No Data

How AVBP did perform over past 52-week?

AVBP's closing price is 64.53% higher than its 52-week low of $17.00 where as its distance from 52-week high of $35.83 is -21.94%.

How many employees does AVBP have?

Number of AVBP employees currently stands at 77.

Link for AVBP official website?

Official Website of AVBP is: https://arrivent.com

How do I contact AVBP?

AVBP could be contacted at phone 628 277 4836 and can also be accessed through its website. AVBP operates from 18 Campus Boulevard Suite 100, Newtown Square, PA 19073, United States.

How many shares of AVBP are traded daily?

AVBP stock volume for the day was 299.05K shares. The average number of AVBP shares traded daily for last 3 months was 535.57K.

What is the market cap of AVBP currently?

The market value of AVBP currently stands at $1.30B with its latest stock price at $27.97 and 46.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	77
Beta	1.36
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

AVBP Company Profile and Key Details

ArriVent BioPharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics